Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States and the Netherlands. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand; and COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. In addition, it engages in laboratory analysis. The company was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P/FC.